Search
EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia
EHA in close collaboration with the Estonian Society of Haematology, the Lithuanian Society of Hematology and the Latvian Hematology Society are organizing the first EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia.
Read moreInternational CML adherence survey launched
The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.
Read moreEHA-GBMTA-AHA Hematology Tutorial
EHA is joining the Georgian Association for Blood and Bone Marrow Transplantation (GBMTA) and Armenian Hematology Association (AHA) to organize the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies.
Read moreAnna Vardi Physician Scientist Research Grant winner 2018
Please tell us more about yourself (name, lab, short bio)
I am Anna Vardi. I am currently working as a Consultant Hematologist at the Hematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece, under the Directorship of Dr.
EHA-ISHBT Hematology Tutorial on Hematological Disorders
Dates: February 28-29, 2020
Location: Chandigarh, India
Chairs: N Varma, P Malhotra, J Gribben
Organized by: European Hematology Association (EHA) & Indian Society of Hematology and Blood Transfusion (ISHBT)
EHA will join ISHBT for a fourth time to organize the EHA-ISHBT Hematology Tutorial, this time in Chandigargh,…
EHA-ISHBT Hematology Tutorial
Date: March 1-3, 2024
Format: In-Person
Location: Hyderabad, India
Chairs: P. K.
Targeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read moreThe Clot Thickens
Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).
Read moreIbrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.
Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- »